Please assess the completion status of the following clinical trial:

Trial Title: SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD.~* On stable doses of furosemide, or alternative loop diuretic for at least one month.~* Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 6.5% ≤ and ≤10.0%)~* eGFR ≥ 45 ml/min.~* Have stable HF symptoms for at least three months prior to consent~* On stable HF therapy for at least three months prior to consent~* Have not been hospitalised for HF for at least three months prior to consent.~* Women of childbearing potential must agree to take precautions to avoid pregnancy throughout the trial and for 4 weeks after intake of the last dose.~Exclusion Criteria:~* A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal~* Systolic BP of \<95mmHg at screening visit.~* Participants on thiazide diuretics.~* Participants receiving renal dialysis~* Participants who have previously had an episode of diabetic ketoacidosis.~* Participants with type 1 diabetes mellitus~* Malignancy (receiving active treatment) or other life threatening disease.~* Pregnant or lactating women~* Participants with difficulty in micturition e.g. severe prostate enlargement~* Allergy to any SGLT2 inhibitor or lactose or galactose intolerance~* Past or current treatment with any SGLT2 inhibitor~* Participants who have participated in any other clinical interventional trial of an investigational medicinal product within 30 days.~* Participants who are unable to give informed consent~* Any other reason considered by the physician to be inappropriate for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin/Placebo (Type: ACTIVE_COMPARATOR): Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
- Placebo/Empagliflozin (Type: ACTIVE_COMPARATOR): Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).